Age-Related Macular Degeneration (AMD)

1. Clinical Overview

Summary

Age-Related Macular Degeneration (AMD) is the leading cause of irreversible blindness in the developed world in people aged over 50 years, affecting approximately 196 million people globally. [1,2] It is a progressive neurodegenerative disease affecting the macula – the central 5-6mm of the retina responsible for high-acuity central vision essential for reading, driving, and facial recognition. AMD exists in two principal forms with distinct pathophysiology, clinical presentation, and management strategies:

Dry AMD (Geographic Atrophy) represents 85-90% of cases and is characterised by drusen (extracellular deposits between the retinal pigment epithelium and Bruch's membrane) and progressive retinal pigment epithelium (RPE) atrophy. [3] This form typically follows a slowly progressive course over years to decades, with gradual central vision deterioration.

Wet AMD (Neovascular/Exudative AMD) accounts for 10-15% of cases but is responsible for approximately 90% of severe vision loss from AMD. [4] It is characterised by choroidal neovascularisation (CNV) – the pathological growth of abnormal blood vessels from the choroid through Bruch's membrane beneath or within the retina, driven by upregulated vascular endothelial growth factor (VEGF). These vessels are fragile and leaky, causing subretinal and intraretinal fluid accumulation, haemorrhage, and ultimately disciform scarring. Wet AMD is a medical emergency requiring urgent assessment and treatment initiation within 2 weeks to prevent irreversible vision loss. [5]

Modern management of wet AMD has been revolutionised by anti-VEGF intravitreal therapy (ranibizumab, aflibercept, brolucizumab, faricimab), which can stabilise vision in approximately 90% of patients and improve vision in 30-40%. [6,7] In contrast, dry AMD currently has limited treatment options, with AREDS2 supplementation slowing progression in intermediate disease, and emerging therapies targeting complement inhibition showing promise for geographic atrophy. [8,9]

Risk factors include advancing age (strongest risk factor), smoking (most important modifiable risk factor, conferring 2-4× increased risk), genetic factors (particularly CFH and ARMS2/HTRA1 variants), cardiovascular disease, obesity, and family history. [10,11,12]

Clinical Pearls

Dry = Drusen = Slow Decline: Yellow-white deposits under the retina. Progressive vision loss over years to decades. No effective treatment except AREDS2 in intermediate stages.

Wet = Neovascularisation = Rapid Loss = Emergency: Choroidal neovascularisation (CNV) causing fluid, blood, and lipid exudation. Can cause devastating vision loss in weeks. Urgent anti-VEGF therapy within 2 weeks.

Amsler Grid Self-Monitoring: Essential home monitoring tool for patients with dry AMD or wet AMD in fellow eye. Daily checking – distorted or wavy lines indicate urgent ophthalmology review.

2-Week Target: NICE and RCOphth mandate treatment initiation within 14 days of wet AMD symptom onset. Every week of delay risks irreversible photoreceptor damage.

OCT is Gold Standard: Optical Coherence Tomography has replaced fluorescein angiography as primary diagnostic and monitoring tool. Non-invasive, rapid, quantifies retinal fluid and thickness.

Fellow Eye Risk: Patients with wet AMD in one eye have approximately 10-15% annual risk of developing wet AMD in the fellow eye over 5 years.

---

2. Epidemiology

Global Burden

Age-Related Macular Degeneration represents a major global health burden:

Demographics

Age-Specific Prevalence

Risk Factors

Protective Factors

---

3. Pathophysiology

Retinal Anatomy - The Macula

Understanding AMD requires detailed knowledge of macular microanatomy:

Macular Layers (Outer to Inner):

1. Choroid: Highly vascularised layer providing oxygen and nutrients to outer retina
2. Bruch's Membrane: Five-layered pentalaminar structure acting as diffusion barrier between choroid and RPE
3. Retinal Pigment Epithelium (RPE): Single layer of hexagonal pigmented cells performing critical functions:
   • Phagocytosis of photoreceptor outer segments (daily renewal)
   • Vitamin A metabolism (visual cycle)
   • Blood-retinal barrier maintenance
   • Growth factor secretion (VEGF, PEDF)
4. Photoreceptor Layer: Highest concentration of cones in fovea (responsible for colour vision and high acuity)
5. Outer Nuclear Layer: Photoreceptor cell bodies
6. Inner Retinal Layers: Bipolar cells, ganglion cells, nerve fiber layer

Fovea: Central 1.5mm zone with highest cone density (~199,000 cones/mm²), rod-free zone, thinnest retina due to displacement of inner layers.

Dry AMD Pathophysiology

Stage 1: Oxidative Stress and Metabolic Dysfunction

The retina is the highest oxygen-consuming tissue per gram in the body, making it particularly susceptible to oxidative damage. [13]

1. Oxidative Injury: Accumulation of reactive oxygen species (ROS) from:

   • Phototransduction (light exposure)
   • High metabolic rate
   • Lipid peroxidation
   • Smoking (systemic oxidative stress)

2. RPE Dysfunction: Aged RPE cells show:

   • Decreased phagocytic capacity
   • Accumulation of lipofuscin (autofluorescent aging pigment)
   • Mitochondrial dysfunction
   • Reduced antioxidant defenses

Stage 2: Drusen Formation

Drusen are extracellular deposits between the RPE and Bruch's membrane, composed of:

• Lipids (esterified and unesterified cholesterol)
• Proteins (amyloid-β, complement components, vitronectin)
• Inflammatory mediators
• Cellular debris

Drusen Classification:

Stage 3: Complement Activation and Inflammation

Drusen contain complement proteins, and genetic variants in complement pathway genes (particularly CFH - Complement Factor H) are strongly associated with AMD. [12]

1. CFH Gene Variant (Y402H): Most common AMD-associated polymorphism

   • Homozygous carriers: 5-7× increased AMD risk
   • Impaired complement regulation
   • Enhanced inflammatory response in macula

2. Local Inflammation: Chronic low-grade inflammation ("para-inflammation"):

   • Microglial activation
   • Complement cascade activation
   • Cytokine release (IL-6, IL-8, TNF-α)

Stage 4: Geographic Atrophy

Progressive RPE cell death leads to sharply demarcated areas of RPE loss:

• Loss of RPE → Loss of overlying photoreceptors → Permanent scotoma
• Typically starts parafoveally, gradually enlarges
• Growth rate: ~1.8 mm²/year (varies widely) [15]
• Foveal involvement → severe central vision loss

Patterns of Atrophy:

• Small/Multifocal: Multiple small areas
• Horseshoe: Spares fovea initially
• Solid/Confluent: Large confluent areas

---

Wet AMD Pathophysiology

Stage 1: Angiogenic Stimulus

Chronic dry AMD changes, particularly thick drusen and RPE dysfunction, create a hypoxic and inflammatory microenvironment leading to:

1. Hypoxia-Inducible Factor (HIF-1α) Activation: Upregulated by:

   • Local hypoxia (impaired choroidal perfusion through thickened Bruch's membrane)
   • Oxidative stress
   • Inflammatory cytokines

2. VEGF Overexpression: [16]

   • Normal RPE secretes VEGF basally (towards choroid) and PEDF (pigment epithelium-derived factor) apically
   • In AMD: VEGF upregulation + PEDF downregulation
   • VEGF-A is primary driver of neovascularisation
   • Isoforms: VEGF₁₂₁, VEGF₁₆₅, VEGF₁₈₉

Stage 2: Choroidal Neovascularisation (CNV)

Abnormal blood vessel growth through Bruch's membrane:

CNV Classification (Historical - OCT now primary):

Modern Classification (OCT-based):

• Macular Neovascularisation (MNV) Type 1, 2, 3
• Corresponds to anatomical location of neovascular complex

Stage 3: Exudation and Haemorrhage

Immature CNV vessels lack tight junctions and pericyte coverage:

1. Vascular Leakage:

   • Subretinal fluid (SRF)
   • Intraretinal fluid (IRF)/cystoid spaces
   • Lipid exudation

2. Haemorrhage:

   • Subretinal haemorrhage (dark red, blocks fluorescence)
   • Sub-RPE haemorrhage (darker, dome-shaped)
   • Vitreous haemorrhage (rare, if breakthrough to vitreous cavity)

3. Pigment Epithelial Detachment (PED):

   • Serous PED: Fluid accumulation
   • Fibrovascular PED: CNV within PED
   • Drusenoid PED: Confluent soft drusen

Stage 4: Fibrosis and Disciform Scar

Chronic untreated or treatment-resistant wet AMD progresses to:

• Subretinal fibrosis
• RPE hyperplasia
• Fibrovascular tissue organisation
• Disciform Scar: Dense fibrous tissue replacing normal retinal architecture → Permanent central scotoma

---

4. Differential Diagnosis

Central vision loss in older adults can result from multiple pathologies. Accurate differentiation is crucial for appropriate management.

Comparison Table: AMD vs Key Differentials

Additional Differentials

Epiretinal Membrane (Macular Pucker):

• Cellophane-like membrane on inner retinal surface
• Metamorphopsia, blurred vision
• OCT: Hyperreflective membrane, retinal distortion
• Management: Observation or vitrectomy if significant

Macular Telangiectasia Type 2:

• Bilateral parafoveal telangiectatic vessels
• Crystalline deposits, right-angle venules
• OCT: Cavitations, loss of inner retinal layers
• Progressive, no effective treatment

Best Disease (Vitelliform Macular Dystrophy):

• Inherited (BEST1 gene)
• "Egg yolk" lesion on fundoscopy
• Abnormal EOG (electro-oculogram)
• Diagnosis in childhood/young adults

Stargardt Disease:

• Juvenile macular dystrophy (ABCA4 gene)
• "Beaten bronze" macula, flecks
• Fundus autofluorescence characteristic
• Progressive, no treatment

---

5. Clinical Presentation

Symptoms

The hallmark symptom distinguishing wet from dry AMD is metamorphopsia – distortion of straight lines appearing wavy, bent, or irregular.

Dry AMD Symptoms

Wet AMD Symptoms

Clinical Pearl: Any patient with known dry AMD reporting sudden onset of metamorphopsia should be assumed to have wet AMD until proven otherwise and requires urgent ophthalmology assessment within 1 week.

Associated Symptoms

Charles Bonnet Syndrome: [17]

• Complex visual hallucinations in patients with severe vision loss
• Hallucinations typically non-threatening: faces, patterns, animals, buildings
• Patient retains insight (knows they are not real)
• Prevalence: 10-30% of patients with severe AMD
• Important: Ask directly – patients often don't volunteer information (fear of being thought "crazy")
• Reassurance is primary management; usually diminishes over time

Examination Findings

Visual Acuity

Distance Visual Acuity (Snellen or ETDRS LogMAR):

• Dry AMD: Gradual decline; may remain 6/12 or better for years in early stages
• Wet AMD: Often rapid decline to 6/60 or worse if untreated

Near Vision:

• Reading acuity (N-point or near LogMAR)
• Often affected earlier and more significantly than distance acuity

NICE Treatment Criteria for Anti-VEGF (Historical - now more flexible): [5]

• Best-corrected visual acuity 6/12 to 6/96
• Modern practice: Treat if vision potentially salvageable, regardless of exact acuity

Amsler Grid Assessment

Technique:

1. Patient wears reading glasses (if used)
2. Holds grid at comfortable reading distance (~30cm)
3. Covers one eye
4. Fixates on central dot
5. Notes any abnormalities while maintaining central fixation

Normal: All lines straight, grid complete, no missing areas

Abnormal Findings:

• Metamorphopsia: Wavy, distorted, bent lines → Suggests wet AMD or progression
• Scotoma: Missing patch or blank area → Atrophy or CNV
• Blurred areas: Reduced clarity

Home Monitoring: Patients with dry AMD or wet AMD in fellow eye should check daily and report changes urgently.

Fundoscopy / Slit-Lamp Biomicroscopy

Dry AMD Findings:

Wet AMD Findings:

---

6. Investigations

Imaging Modalities

Modern AMD diagnosis and management relies heavily on multimodal imaging. Optical Coherence Tomography (OCT) has become the gold standard for diagnosis, monitoring, and treatment decisions.

6.1 Optical Coherence Tomography (OCT)

Principle: Near-infrared light interferometry creating cross-sectional retinal images at ~5-7 μm resolution.

Indications:

• Diagnosis of wet AMD
• Quantification of retinal fluid (subretinal and intraretinal)
• Monitoring treatment response
• Detection of dry AMD features (drusen, atrophy)

Key OCT Findings in Dry AMD:

Key OCT Findings in Wet AMD:

Quantitative Metrics:

• Central Subfield Thickness (CST): Normal ~250-280 μm; > 300 μm suggests macular thickening
• Fluid Volume: Some OCT platforms quantify SRF and IRF volume
• Pigment Epithelial Detachment Height: Measured in micrometers

Treatment Decisions:

• Presence of SRF or IRF → Indicates disease activity → Re-treatment with anti-VEGF
• Dry retina (no fluid) → Observe or extend treatment interval

6.2 OCT Angiography (OCT-A)

Principle: Motion-contrast imaging detecting blood flow in retinal and choroidal vasculature without dye injection.

Advantages:

• Non-invasive (no IV access required)
• Rapid acquisition
• Depth-resolved (separate superficial, deep, choriocapillaris layers)
• Visualises CNV morphology and flow

OCT-A Findings:

• MNV Detection: Tangled "sea fan" or "medusa head" neovascular complex
• Flow Quantification: Area and density of CNV network
• Choriocapillaris Flow Deficits: Areas of reduced perfusion in dry AMD

Limitations:

• Cannot image active leakage (unlike FFA)
• Artefacts from media opacity (cataract)
• Segmentation errors in presence of large PEDs

6.3 Fluorescein Angiography (FFA)

Principle: IV injection of sodium fluorescein (10% solution), rapid sequence photographs during dye transit. Fluorescein has molecular weight 376 Da – leaks from fenestrated choriocapillaris and abnormal vessels.

Phases:

1. Choroidal Phase (10-15 seconds): Choroidal filling (patchy "lobular" pattern)
2. Arterial Phase (15 seconds): Retinal artery filling
3. Arteriovenous Phase (20-30 seconds): Retinal vein filling
4. Recirculation/Late Phase (5-10 minutes): Staining and leakage assessment

Classic CNV (Type 2):

• Early: Well-demarcated area of hyperfluorescence
• Late: Progressive leakage, obscures lesion boundaries ("leaking classic CNV")

Occult CNV (Type 1):

• Fibrovascular PED: Irregular RPE elevation with stippled hyperfluorescence
• Late Leakage of Undetermined Source: Ill-defined leakage without classic CNV

Current Role: Largely replaced by OCT/OCT-A for diagnosis; occasionally used for:

• Polypoidal choroidal vasculopathy (PCV) - better seen on ICGA
• Ambiguous cases where OCT is equivocal
• Peripheral CNV (outside OCT field)

Adverse Effects: Nausea (5%), rash (less than 1%), anaphylaxis (rare, 1:10,000)

6.4 Indocyanine Green Angiography (ICGA)

Principle: IV injection of indocyanine green dye (larger molecule, 98% protein-bound) - remains in choroidal circulation.

Indications:

• Polypoidal Choroidal Vasculopathy (PCV): Branching vascular network with polypoidal dilations
• Occult CNV: Better choroidal imaging than FFA
• Pigmented lesions (better penetration through blood, RPE)

Findings:

• Polypoidal lesions: Hyperfluorescent polyps on ICGA (not visible on FFA)
• PCV more common in Asian populations

6.5 Fundus Autofluorescence (FAF)

Principle: Imaging intrinsic fluorescence of lipofuscin in RPE (excitation 488nm, emission 500-750nm).

Normal: Uniform background autofluorescence; fovea is hypofluorescent (luteal pigment absorption)

Dry AMD Findings:

• Increased FAF: Lipofuscin accumulation (drusen may appear hyperautofluorescent)
• Decreased FAF: RPE atrophy (geographic atrophy appears dark/hypoautofluorescent)
• Geographic Atrophy Margins: Hyperautofluorescent rim indicates active progression

Wet AMD Findings:

• Blocked Fluorescence: Haemorrhage appears dark
• Increased FAF: Subretinal fibrosis (hyperautofluorescent)

Clinical Utility:

• Monitor geographic atrophy progression
• Identify high-risk eyes (patterns of FAF abnormality predict progression) [15]

6.6 Colour Fundus Photography

Standard 7-Field Protocol (modified ETDRS):

• Documents overall retinal status
• Baseline documentation
• Medico-legal record

Ultra-Widefield Imaging (Optos):

• 200° field of view
• Detects peripheral lesions

Visual Function Testing

Genetic Testing

Clinical Genetic Testing Panels available for:

• CFH (Complement Factor H - Y402H variant)
• ARMS2/HTRA1
• C3, C2, CFB (complement pathway genes)

Utility:

• Risk stratification (particularly young-onset AMD, strong family history)
• Research participation
• Future personalised therapies

Limitations:

• Does not change current clinical management
• Complex genetic counselling required
• Not routinely recommended by NICE or RCOphth [5]

---

7. Management

7.1 Management Algorithm

┌────────────────────────────────────────────────────────────┐
│        SUSPECTED AMD - Age > 50 + Central Vision Loss       │
└─────────────────────┬──────────────────────────────────────┘
                      │
                      ▼
        ┌─────────────────────────────┐
        │   INITIAL ASSESSMENT        │
        │   - Visual acuity (BCVA)    │
        │   - Amsler grid             │
        │   - Dilated fundoscopy      │
        │   - OCT macula              │
        └──────────┬──────────────────┘
                   │
      ┌────────────┴────────────┐
      │                         │
      ▼                         ▼
┌──────────────┐        ┌──────────────────┐
│   DRY AMD    │        │    WET AMD       │
└──────┬───────┘        │  (CNV on OCT)    │
       │                └────────┬─────────┘
       │                         │
       │                    ** URGENT **
       │                         │
       ▼                         ▼
┌─────────────────────┐   ┌─────────────────────────┐
│ CLASSIFY SEVERITY:  │   │ FAST-TRACK REFERRAL     │
│                     │   │ - Target: less than 1 week       │
│ - Early AMD         │   │ - Treatment: less than 2 weeks   │
│   (Small drusen)    │   │                         │
│                     │   │ CONFIRM WET AMD:        │
│ - Intermediate AMD  │   │ - OCT: SRF/IRF/CNV     │
│   (Medium drusen    │   │ - OCT-A: Flow in CNV   │
│   or RPE changes)   │   │ - FFA if required      │
│                     │   │                         │
│ - Advanced Dry AMD  │   └──────────┬──────────────┘
│   (Geographic       │              │
│   Atrophy)          │              ▼
│                     │   ┌──────────────────────────┐
└──────┬──────────────┘   │  ANTI-VEGF THERAPY       │
       │                  │  - Ranibizumab or        │
       │                  │  - Aflibercept or        │
       │                  │  - Faricimab or          │
       │                  │  - Brolucizumab          │
       ▼                  │                          │
┌──────────────────────┐  │  LOADING PHASE:          │
│ MANAGEMENT:          │  │  3 monthly injections    │
│                      │  │                          │
│ Early AMD:           │  └──────────┬───────────────┘
│ - Education          │             │
│ - Amsler grid        │             ▼
│ - Annual review      │  ┌──────────────────────────┐
│                      │  │  MAINTENANCE PHASE:      │
│ Intermediate AMD:    │  │                          │
│ - AREDS2 vitamins    │  │  Choose regimen:         │
│ - Smoking cessation  │  │  • Treat-and-Extend (TaE)│
│ - 6-monthly review   │  │    - OCT every visit     │
│                      │  │    - If dry: extend by   │
│ Advanced Dry AMD:    │  │      2-4 weeks           │
│ - Low vision support │  │    - If fluid: return to │
│ - VI registration    │  │      last dry interval   │
│ - Emerging therapies │  │                          │
│   (pegcetacoplan)    │  │  OR                      │
│                      │  │                          │
│ ALL:                 │  │  • PRN (as needed)       │
│ - Address modifiable │  │    - Monthly OCT         │
│   risk factors       │  │    - Inject if fluid     │
│ - Consider fellow    │  │                          │
│   eye monitoring     │  │  OR                      │
└──────────────────────┘  │                          │
                          │  • Fixed (monthly/q8wk)  │
                          │    - Less common now     │
                          └──────────────────────────┘

7.2 Dry AMD Management

Currently, no treatment can reverse geographic atrophy or restore lost photoreceptors in dry AMD. Management focuses on slowing progression and optimising residual vision.

7.2.1 Risk Factor Modification

Smoking Cessation: [10]

• Most important modifiable intervention
• Current smokers: 2.4-3.5× increased AMD risk
• Benefits accrue over 20+ years after cessation
• Refer to smoking cessation services
• Pharmacotherapy: Varenicline, bupropion, nicotine replacement

Dietary Modification:

• Mediterranean diet: High fruits, vegetables, fish, nuts, olive oil
• Increase lutein and zeaxanthin: Dark leafy greens (kale, spinach), egg yolks
• Omega-3 fatty acids: Oily fish 2×/week (salmon, mackerel, sardines)
• Reduce saturated fats and refined carbohydrates

Cardiovascular Risk Management:

• Control hypertension (target less than 140/90 mmHg)
• Manage hyperlipidaemia
• Optimise diabetic control (if diabetic)

Weight Management:

• BMI less than 25 kg/m² target
• Reduce abdominal obesity

7.2.2 AREDS2 Supplementation

Age-Related Eye Disease Study 2 (AREDS2) demonstrated slowed progression to late AMD in intermediate AMD. [8]

AREDS2 Formulation (Daily Dose):

• Vitamin C: 500 mg
• Vitamin E: 400 IU
• Lutein: 10 mg
• Zeaxanthin: 2 mg
• Zinc (as zinc oxide): 80 mg
• Copper (as cupric oxide): 2 mg

Efficacy:

• 25-30% reduction in progression to late AMD over 5 years in intermediate AMD
• No benefit in early AMD or established late AMD
• Lutein/zeaxanthin replaced beta-carotene (lung cancer risk in smokers)

Indications (NICE NG82): [5]

• Intermediate AMD (defined as extensive medium drusen or ≥1 large drusen)
• Late AMD in one eye (to protect fellow eye)

Contraindications/Cautions:

• Smokers: Avoid beta-carotene formulations
• Anticoagulation: High-dose vitamin E may increase bleeding risk (discuss with prescriber)

Availability:

• Over-the-counter (not NHS-funded in UK)
• Multiple brands available (MacuShield, Viteyes, PreserVision, etc.)

7.2.3 Monitoring and Surveillance

Patient Education:

• Amsler grid use: Daily self-monitoring; report distortion urgently
• Symptoms requiring urgent review: Metamorphopsia, sudden vision loss, dense central scotoma
• Fellow eye risk: Explain increased risk in second eye

7.2.4 Emerging Therapies for Geographic Atrophy

Complement Inhibition:

1. Pegcetacoplan (Syfovre) - FDA approved 2023: [9]

   • C3 complement inhibitor
   • Intravitreal injection every 25-60 days
   • OAKS and DERBY trials: 20-22% reduction in geographic atrophy growth at 24 months
   • Caution: Increased risk of new-onset wet AMD (~12%)
   • Not yet approved in UK (under NICE evaluation)

2. Avacincaptad Pegol (Izervay) - FDA approved 2023:

   • C5 complement inhibitor
   • Monthly intravitreal injection
   • GATHER1 trial: 27% reduction in GA growth at 12 months
   • Similar wet AMD conversion risk

Other Investigational Therapies:

• Gene therapy: CRISPR-based approaches (early trials)
• Cell therapy: RPE stem cell transplantation (experimental)
• Neuroprotection: Ciliary neurotrophic factor (CNTF), brimonidine

Current UK Status: Pegcetacoplan and avacincaptad not routinely available; patients may access via private prescription or clinical trials.

7.2.5 Low Vision Rehabilitation

For patients with significant irreversible vision loss (VA less than 6/18 or significant central scotoma):

Certifiable Visual Impairment (UK):

• Sight Impaired (Partially Sighted): VA 3/60-6/60 or significant field loss
• Severely Sight Impaired (Blind): VA less than 3/60 or VA less than 6/60 with very contracted field

Low Vision Services:

• Optical Aids: Handheld magnifiers, stand magnifiers, electronic magnifiers (CCTV), telescopes
• Non-Optical Aids: Large print, high-contrast materials, improved lighting, writing guides
• Technology: Screen readers, voice-activated assistants, smartphone accessibility features
• Eccentric Viewing Training: Learn to use preferred retinal locus (PRL) outside damaged macula

Occupational Therapy: Home safety assessment, mobility training

Support Organisations (UK):

• Royal National Institute of Blind People (RNIB)
• Macular Society
• Local social services registration for blind/partially sighted

Psychological Support: Screen for depression (common in visually impaired patients); offer counselling/CBT

---

7.3 Wet AMD Management

7.3.1 Intravitreal Anti-VEGF Therapy

Anti-VEGF therapy has revolutionised wet AMD outcomes, transforming it from an inevitably blinding condition to one that can be stabilised or improved in most patients.

Mechanism of Action:

• Bind and neutralise VEGF-A (primary driver of CNV)
• Reduce vascular permeability
• Inhibit neovascularisation
• Decrease exudation and haemorrhage

Available Agents (UK):

Landmark Trials:

7.3.2 Treatment Regimens

Loading Phase (Universal for All Agents):

• 3 consecutive monthly injections (baseline, month 1, month 2)
• Establishes disease control
• Achieves maximal fluid reduction

Maintenance Phase (choose based on local protocols, patient factors, and clinician preference):

1. Treat-and-Extend (TaE) - Most commonly used in UK NHS: [19]

• Principle: Inject every visit; extend interval if retina dry (no SRF/IRF on OCT)
• Protocol:
  • "If OCT shows dry retina: Extend by 2-4 weeks (up to maximum 12-16 weeks depending on agent)"
  • "If OCT shows fluid recurrence: Return to last interval where retina was dry"
  • "Minimum interval: Usually 8 weeks"
  • "Maximum interval: 12-16 weeks (depending on agent; faricimab up to 16 weeks)"
• Advantages: Fewer visits than PRN or fixed; proactive (prevents fluid accumulation)
• Disadvantages: Requires reliable patient attendance

2. Pro Re Nata (PRN) / "As Needed":

• Principle: Inject only when disease activity detected
• Protocol:
  • Monthly monitoring visits with OCT
  • "Re-treatment if: New/persistent SRF or IRF, new haemorrhage, VA loss > 5 letters, increased retinal thickness"
• Advantages: Fewer injections overall
• Disadvantages: More clinic visits (monthly OCT), reactive (allows fluid to accumulate before treating)

3. Fixed Dosing:

• Principle: Regular injections at fixed intervals regardless of OCT findings
• Protocol: Monthly or every 8 weeks (aflibercept)
• Advantages: Simplest; maximal disease suppression
• Disadvantages: Over-treatment in some patients; high treatment burden

Real-World Outcomes: [20]

• Trial outcomes often better than real-world practice (treatment burden, compliance)
• Real-world: ~7-8 injections/year (vs 12-13 in trials)
• Vision stabilisation in ~85-90%; improvement in ~25-30% (less than trials)
• Undertreatment is main cause of suboptimal outcomes

7.3.3 Injection Procedure

Pre-Procedure:

• Informed consent (risks: endophthalmitis 1:2,000, retinal detachment 1:3,000, submacular haemorrhage, raised IOP)
• Check correct eye, correct drug, correct dose

Procedure (Sterile technique):

1. Topical anaesthesia: Proxymetacaine 0.5% drops
2. Antisepsis: Povidone-iodine 5% to conjunctiva and lids (gold standard; most important step in preventing endophthalmitis)
3. Eyelid speculum placement
4. Injection site: 3.5-4.0 mm posterior to limbus (pseudophakic/aphakic) or 3.0-3.5 mm (phakic)
5. Injection: 30-gauge needle, perpendicular to sclera, inject 0.05 mL
6. Post-injection: Check for light perception, measure IOP if indicated
7. No topical antibiotics (no evidence of benefit; may select resistant organisms)

Post-Procedure Instructions:

• Report immediately if: Pain, redness, photophobia, floaters, vision loss (suspect endophthalmitis)
• Subconjunctival haemorrhage is common and harmless (resolves in 1-2 weeks)

Follow-up:

• Review in 4-8 weeks (depending on regimen)
• OCT at each visit to assess response

7.3.4 Treatment Response and Monitoring

Anatomical Response (OCT):

• Good Response: Complete resolution of SRF and IRF
• Partial Response: Reduction but not complete resolution of fluid
• Non-Response: Persistent fluid despite regular injections

Functional Response (Visual Acuity):

• Improved: ≥15 letters (3 lines) gain
• Stable: ±14 letters
• Declined: ≥15 letters loss

Treatment Targets:

• Ideal: Dry retina on OCT + stable or improved VA
• Acceptable: Minimal SRF (if chronic, non-progressive) + stable VA
• Suboptimal: Persistent IRF, progressive vision loss

When to Consider Alternative Agents:

• Persistent fluid despite regular injections (tachyphylaxis)
• Intolerable treatment burden (consider longer-acting agents like faricimab)
• Adverse effects (e.g., brolucizumab-related inflammation)

7.3.5 Photodynamic Therapy (PDT)

Verteporfin PDT - Rarely used for wet AMD now (superseded by anti-VEGF):

Principle:

• IV verteporfin (photosensitising agent)
• Activated by 689nm laser
• Selective occlusion of CNV vessels

Current Indications (very limited):

• Polypoidal Choroidal Vasculopathy (PCV): Combination PDT + anti-VEGF may be superior to anti-VEGF alone in some PCV cases
• Chronic Central Serous Chorioretinopathy (not AMD)

Procedure:

• IV verteporfin 6 mg/m² over 10 minutes
• Wait 15 minutes
• Apply 689nm laser (83 seconds, 50 J/cm²)

Adverse Effects:

• Photosensitivity: Avoid sunlight/bright light for 48 hours (skin and eyes)
• Visual disturbances, injection site reactions
• Back pain during infusion (common)

7.3.6 Combination and Adjunctive Therapies

Anti-VEGF + PDT:

• Used in some PCV cases (more common in Asian populations)
• EVEREST II trial suggested benefit in certain PCV subtypes

Corticosteroids (Not Standard):

• Intravitreal dexamethasone implant (Ozurdex) or triamcinolone
• May reduce exudation
• Risk: Cataract, glaucoma
• Reserved for refractory cases with inflammatory component

---

8. Complications

Vision-Related Complications

Functional and Psychosocial Complications

Treatment-Related Complications

Anti-VEGF Injection Complications:

---

9. Prognosis and Outcomes

Natural History (Untreated)

With Modern Treatment (Anti-VEGF Era)

Wet AMD Treatment Outcomes (Clinical Trials): [6,7]

Real-World Outcomes (Observational Studies): [20]

• Vision maintenance: 80-85% (lower than trials)
• Vision improvement: 20-30% (lower than trials)
• Undertreatment (fewer injections than trials) is main factor

Prognostic Factors for Better Visual Outcomes:

Prognostic Factors for Poor Outcomes:

• Large initial lesion (> 4 disc areas)
• Subretinal fibrosis/disciform scar
• Submacular haemorrhage (large)
• Poor baseline VA (less than 6/60)
• Delayed treatment (> 4-6 weeks from symptoms)
• Poor treatment adherence/undertreatment

Long-Term Prognosis

5-Year Outcomes (Anti-VEGF):

• Continued treatment: 50-60% maintain vision gains from year 1-2
• Treatment cessation: Often leads to recurrence and vision loss
• Geographic atrophy development: Can occur in ~20% of treated wet AMD eyes (particularly around CNV scar)

Fellow Eye Risk:

• 10-15% annual risk of wet AMD in fellow eye (if one eye affected)
• 43% cumulative 5-year risk
• Monitor closely with OCT and Amsler grid

Treatment Duration:

• Most patients require indefinite treatment (years)
• Some may achieve extended intervals (12-16 weeks) with newer agents (faricimab)
• Rare spontaneous CNV regression

---

10. Evidence and Guidelines

Key Guidelines

Landmark Trials and Evidence

Anti-VEGF Trials:

Dosing Regimen Trials:

Dry AMD and Supplementation Trials:

Quality of Life and Economic Impact

• VISION Study: AMD associated with similar quality of life impact as metastatic cancer or stroke [Williams 2001]
• Economic burden (UK): Estimated £1.6 billion annually (direct + indirect costs)
• Cost-effectiveness: Anti-VEGF highly cost-effective (QALY gains); bevacizumab most cost-effective agent [18]

---

11. Examination Focus

Common MRCP / Ophthalmology Exam Scenarios

Viva Questions and Model Answers

Q1: What is the key pathological difference between dry and wet AMD?

Model Answer: "Dry AMD is characterised by drusen – extracellular deposits between the retinal pigment epithelium and Bruch's membrane – and progressive geographic atrophy of the RPE. Wet AMD, in contrast, involves choroidal neovascularisation – the abnormal growth of fragile, leaky blood vessels from the choroid through Bruch's membrane into or beneath the retina, driven by upregulated VEGF. Wet AMD accounts for only 10-15% of AMD cases but is responsible for 90% of severe vision loss."

---

Q2: A 72-year-old woman presents with sudden onset of distorted vision in her right eye over 5 days. What is your differential diagnosis and initial management?

Model Answer: "The key symptom is metamorphopsia (distortion), which is highly suggestive of a macular pathology. Given the acute onset and age, the main differentials are:

1. Wet AMD (most likely) – choroidal neovascularisation
2. Central serous chorioretinopathy (less likely at this age; more common 30-50 years)
3. Macular hole (though usually slower onset)
4. Epiretinal membrane (usually gradual)

Initial Management:

• Urgent assessment: Within 1 week (NICE 2-week target)
• Examinations: Best-corrected visual acuity, Amsler grid, dilated fundoscopy (look for subretinal fluid, haemorrhage, CNV)
• OCT macula: Gold standard – will show subretinal or intraretinal fluid, CNV, PED if wet AMD
• OCT angiography: Non-invasive visualisation of CNV
• If wet AMD confirmed: Initiate anti-VEGF therapy within 2 weeks (loading phase: 3 monthly injections, then treat-and-extend or PRN maintenance)"

---

Q3: What OCT finding indicates active wet AMD requiring treatment?

Model Answer: "The presence of subretinal fluid (SRF) or intraretinal fluid (IRF) on OCT indicates active disease. On OCT, fluid appears as hyporeflective (dark) spaces – subretinal fluid is seen between the neurosensory retina and the RPE, while intraretinal fluid appears as cystoid spaces within the retinal layers. Other features supporting active wet AMD include pigment epithelial detachment (PED), subretinal hyperreflective material (SHRM) representing blood, fibrin, or CNV tissue, and the neovascular complex itself (best visualised on OCT angiography). The treatment decision is primarily based on the presence of fluid – a 'dry' retina on OCT suggests disease control and may allow interval extension in a treat-and-extend regimen."

---

Q4: What is the strongest modifiable risk factor for AMD, and what is the evidence?

Model Answer: "Smoking is the strongest modifiable risk factor for AMD. Current smokers have a 2.4 to 3.5-fold increased risk of AMD compared to never-smokers, based on meta-analyses of cohort studies. [10] The risk is dose-dependent, with pack-years correlating with AMD severity. Smoking cessation reduces risk, though the benefit accrues gradually over 20+ years. The mechanism involves oxidative stress (increased reactive oxygen species damaging RPE and photoreceptors), impaired choroidal perfusion (nicotine-induced vasoconstriction), and chronic inflammation. Smoking cessation is therefore the single most important lifestyle intervention for AMD prevention and should be strongly encouraged in all patients with AMD or at high risk."

---

Q5: A patient with dry AMD asks about vitamin supplements. What do you advise?

Model Answer: "For patients with intermediate AMD – defined as extensive medium drusen or at least one large drusen – or late AMD in one eye, I would recommend AREDS2 supplementation. The AREDS2 trial [8] demonstrated a 25-30% reduction in progression to late AMD over 5 years in these high-risk patients. The formulation includes:

• Vitamin C 500 mg
• Vitamin E 400 IU
• Lutein 10 mg
• Zeaxanthin 2 mg
• Zinc 80 mg
• Copper 2 mg

Importantly, lutein and zeaxanthin replace beta-carotene from the original AREDS formulation because beta-carotene was associated with increased lung cancer risk in smokers. I would emphasise that:

• These supplements slow progression in intermediate AMD but do not reverse damage or prevent AMD onset in early AMD.
• They are available over-the-counter (not NHS-funded in the UK).
• They should be combined with smoking cessation (most important), a healthy diet rich in leafy greens and oily fish, and cardiovascular risk management."

---

Q6: Explain the principle of 'treat-and-extend' for wet AMD.

Model Answer: "Treat-and-extend (TaE) is a proactive treatment regimen for wet AMD that aims to maintain disease control while minimising treatment burden. [19] The principle is:

1. Inject at every visit (proactive, not reactive)
2. Assess OCT for retinal fluid:
   • If retina is dry (no subretinal or intraretinal fluid): Extend the interval by 2-4 weeks (up to a maximum of 12-16 weeks depending on agent)
   • If fluid recurs: Shorten the interval back to the last interval where the retina was dry
3. Continue indefinitely – most patients require long-term treatment

Advantages over PRN:

• Proactive (prevents fluid accumulation and photoreceptor damage rather than waiting for recurrence)
• Fewer clinic visits than monthly monitoring (PRN requires monthly OCT even if not injecting)
• Better real-world outcomes than PRN

Advantages over fixed monthly:

• Fewer injections overall (reducing treatment burden and cost)
• Individualised to patient's disease activity

TaE is now the preferred regimen in most UK NHS services."

---

OSCE Station: Counselling a Patient About Wet AMD

Scenario: Mrs. Jones, a 68-year-old woman, has just been diagnosed with wet AMD in her right eye. You are the ophthalmology registrar. Explain the diagnosis and treatment plan.

Key Points to Cover:

1. Explain the diagnosis in lay terms:

   • "You have a condition called wet age-related macular degeneration in your right eye."
   • "The macula is the central part of the retina at the back of your eye, responsible for detailed vision like reading and recognising faces."
   • "In wet AMD, abnormal blood vessels grow beneath the macula and leak fluid, causing the central part of your vision to become blurred or distorted."

2. Address concerns:

   • "Will I go blind?" → "Wet AMD affects central vision, but peripheral vision is preserved – you will always be able to get around and navigate. With treatment, we can stabilise or even improve your vision in most cases."

3. Explain treatment:

   • "We treat wet AMD with injections of medicine into the eye called anti-VEGF therapy. This medicine blocks the signal that causes abnormal blood vessels to grow and leak."
   • "You'll need 3 injections, one month apart, to start (loading phase), then ongoing injections every 2-4 months depending on how your eye responds."
   • "The injection is done with local anaesthetic drops so you shouldn't feel pain – just some pressure. The procedure takes a few minutes."

4. Set realistic expectations:

   • "The goal is to stop your vision getting worse. About 90% of people maintain their vision with treatment, and 30-40% actually improve."
   • "Treatment is most effective if started early, which is why we want to begin within the next 2 weeks."

5. Discuss monitoring:

   • "You'll use an Amsler grid at home daily to check for any changes in your vision. If you notice new distortion or a dark spot, contact us urgently."
   • "Your other eye is also at risk – about a 10-15% chance per year – so we'll monitor it closely too."

6. Encourage questions and provide support:

   • "Do you have any questions?"
   • Provide written information and Macular Society contact details.

---

SBA Practice Question

Question: A 75-year-old man with known dry AMD in both eyes presents to the emergency eye clinic with a 4-day history of sudden distortion of vision in his right eye. Visual acuity is 6/24 in the right eye (previously 6/9) and 6/18 in the left eye. OCT of the right eye shows subretinal fluid and a hyperreflective lesion beneath the retina. What is the most appropriate next step in management?

A) Reassure and review in 3 months
B) Prescribe AREDS2 vitamin supplements
C) Arrange urgent fluorescein angiography
D) Initiate intravitreal anti-VEGF therapy within 2 weeks
E) Refer for photodynamic therapy

Answer: D

Explanation: This patient has developed wet AMD (metamorphopsia, subretinal fluid, and choroidal neovascularisation on OCT). The standard of care is urgent anti-VEGF therapy, ideally within 2 weeks of symptom onset (NICE NG82 guideline). [5] Fluorescein angiography (C) is no longer required for diagnosis in most cases as OCT is the gold standard. AREDS2 (B) is for intermediate dry AMD, not wet AMD. Photodynamic therapy (E) has been superseded by anti-VEGF. Delay (A) would result in irreversible vision loss.

---

12. Patient and Layperson Explanation

What is Age-Related Macular Degeneration?

Age-Related Macular Degeneration, or AMD, is an eye condition that affects the macula – the central part of the retina at the back of your eye. The macula is responsible for the sharp, detailed vision you need for activities like reading, driving, and recognising people's faces.

As we age, the macula can become damaged. This causes the central part of your vision to become blurred, distorted, or develop a blank spot. AMD is the leading cause of vision loss in people over 50 in developed countries.

Important to know: AMD affects central vision only. Your peripheral (side) vision remains intact, so you can still get around, navigate your home, and avoid obstacles. Most people with AMD do not go completely blind.

---

What are the Two Types of AMD?

There are two main types:

1. Dry AMD (Geographic Atrophy) – 85-90% of cases

• This is the more common, slower form.
• Yellow deposits called drusen build up under the retina over time.
• Vision loss is gradual, occurring over years or even decades.
• Currently, there is no treatment to reverse dry AMD, but vitamin supplements (AREDS2) can slow its progression in some people.

2. Wet AMD (Neovascular AMD) – 10-15% of cases

• This is less common but more serious.
• Abnormal blood vessels grow under the retina and leak fluid and blood.
• Vision loss can be sudden and severe, happening over days to weeks.
• Wet AMD is a medical emergency but is treatable with injections into the eye if caught early.

---

What are the Symptoms?

Dry AMD symptoms (gradual):

• Difficulty reading small print
• Needing brighter light to see
• Colours appearing faded
• Gradual blurring of central vision

Wet AMD symptoms (sudden – seek urgent help):**

• Distorted vision – straight lines (like door frames or venetian blinds) appear wavy or bent
• A dark or blank spot in the centre of your vision
• Sudden blurring or loss of central vision

If you notice sudden distortion or vision loss, contact your eye clinic or optometrist immediately – treatment works best when started early.

---

What Causes AMD?

AMD is caused by a combination of aging, genetics, and lifestyle factors. The exact cause isn't fully understood, but risk factors include:

---

How is AMD Diagnosed?

Your optometrist or eye doctor will perform:

• Visual acuity test (reading letters on a chart)
• Amsler grid test (looking at a grid to detect distortion)
• Eye examination (looking at the back of your eye with special instruments)
• OCT scan – a quick, painless scan that takes detailed pictures of your retina

---

How is Wet AMD Treated?

Wet AMD is treated with anti-VEGF injections:

• What is it? Medicine injected directly into the eye to stop the abnormal blood vessels from leaking.
• Does it hurt? The eye is numbed with drops first. You may feel some pressure, but it's usually not painful.
• How often? Initially, you'll need 3 injections, one month apart. After that, injections are usually every 2-4 months, depending on how your eye responds.
• Does it work? Yes! About 90% of people maintain their vision, and 30-40% actually improve. The key is starting treatment early.

---

How is Dry AMD Managed?

Currently, there is no cure for dry AMD, but you can slow its progression:

1. AREDS2 vitamin supplements (if you have intermediate AMD):

   • Contains vitamins C, E, lutein, zeaxanthin, and zinc
   • Available over-the-counter (not free on the NHS in the UK)
   • Reduces risk of progression by about 25%

2. Stop smoking (most important!)

3. Healthy diet: Eat plenty of leafy greens, fish, nuts, and colourful vegetables.

4. Monitor at home with an Amsler grid: Check your vision daily. If straight lines appear wavy, contact your eye clinic urgently – it could mean wet AMD is developing.

5. Regular check-ups: Your eye doctor will monitor your eyes regularly.

---

What About My Other Eye?

If you have wet AMD in one eye, there is about a 10-15% chance per year that the other eye will develop wet AMD too. That's why:

• You should monitor your vision daily with an Amsler grid
• Attend all follow-up appointments
• Report any sudden changes (distortion, blurring, dark spots) immediately

---

Will I Go Completely Blind?

Most people with AMD do not go completely blind. AMD affects central vision (reading, faces, driving) but not peripheral vision (getting around, seeing movement, avoiding obstacles).

With modern treatments for wet AMD, and careful monitoring and lifestyle changes for dry AMD, most people maintain useful vision and independence.

---

What Support is Available?

If you have significant vision loss, help is available:

• Low vision clinics: Magnifiers, special glasses, electronic aids
• Occupational therapy: Home adaptations, mobility training
• Support organisations:
  • "Macular Society (UK): 0300 3030 111, macularsociety.org"
  • "RNIB (Royal National Institute of Blind People): 0303 123 9999, rnib.org.uk"
• Social services: Registration as sight impaired or severely sight impaired can unlock additional support

---

Key Takeaways

✅ AMD is common – it's the leading cause of vision loss in older adults
✅ Dry AMD is slow; wet AMD is a sudden emergency
✅ Stop smoking – the single most important thing you can do
✅ Use an Amsler grid daily – report distortion immediately
✅ Wet AMD is treatable with injections – treatment works best when started early
✅ You will not go completely blind – peripheral vision is preserved
✅ Help and support are available

---

13. References

Primary Sources and Landmark Studies

1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-e116. doi:10.1016/S2214-109X(13)70145-1 PMID: 25104651

2. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752-756. doi:10.1136/bjophthalmol-2011-301109 PMID: 22329913

3. Holz FG, Schmitz-Valckenberg S, Fleckenstein M. Recent developments in the treatment of age-related macular degeneration. J Clin Invest. 2014;124(4):1430-1438. doi:10.1172/JCI71029 PMID: 24691477

4. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606-2617. doi:10.1056/NEJMra0801537 PMID: 18550876

5. National Institute for Health and Care Excellence. Age-related macular degeneration: diagnosis and management (NG82). 2018 (updated 2024). Available at: https://www.nice.org.uk/guidance/ng82

6. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. doi:10.1056/NEJMoa054481 PMID: 17021318

7. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548. doi:10.1016/j.ophtha.2012.09.006 PMID: 23084240

8. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005-2015. doi:10.1001/jama.2013.4997 PMID: 23644932

9. Liao DS, Grossi FV, El Mehdi D, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127(2):186-195. doi:10.1016/j.ophtha.2019.07.011 PMID: 31371022

10. Thornton J, Edwards R, Mitchell P, et al. Smoking and age-related macular degeneration: a review of association. Eye (Lond). 2005;19(9):935-944. doi:10.1038/sj.eye.6701978 PMID: 16151432

11. Klaver CC, Wolfs RC, Assink JJ, et al. Genetic risk of age-related maculopathy: population-based familial aggregation study. Arch Ophthalmol. 1998;116(12):1646-1651. doi:10.1001/archopht.116.12.1646 PMID: 9869796

12. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385-389. doi:10.1126/science.1109557 PMID: 15761122

13. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85(3):845-881. doi:10.1152/physrev.00021.2004 PMID: 15987797

14. Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018;63(6):782-815. doi:10.1016/j.survophthal.2018.05.005 PMID: 29859199

15. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al; FAM-Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007;143(3):463-472. doi:10.1016/j.ajo.2006.11.041 PMID: 17239336

16. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859-870. doi:10.1097/01.iae.0000242842.14624.e7 PMID: 17031284

17. Cox TM, ffytche DH. Negative outcome Charles Bonnet syndrome. Br J Ophthalmol. 2014;98(9):1236-1239. doi:10.1136/bjophthalmol-2014-304705 PMID: 24729078

18. Martin DF, Maguire MG, Fine SL, et al; CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. doi:10.1016/j.ophtha.2012.03.053 PMID: 22555112

19. Wykoff CC, Croft DE, Brown DM, et al; TREX-AMD Study Group. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514-2522. doi:10.1016/j.ophtha.2015.08.009 PMID: 26391465

20. Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220-226. doi:10.1136/bjophthalmol-2014-305327 PMID: 25193672

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions should account for individual patient circumstances and local protocols. Always consult appropriate specialists and current guidelines for patient management.